Registry of Ollier Disease and Maffucci Syndrome

Ollier Disease Clinical Trial

— ROM  

Official title:

Registry of Ollier Disease and Maffucci Syndrome That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Quality of Life Data. Data Are Linked to Patients Biological Sample

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04134572
• Other study ID #: 378/2017
• Status: Recruiting
• Start date: January 16, 2017
• Est. completion date: January 2032

Study information

• Verified date: September 2023
• Source: Istituto Ortopedico Rizzoli
• Contact: Marina Mordenti, PhD
• Phone: +39 05 6366062
• Email: marina.mordenti[@]ior.it
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

REM is a retrospective and prospective registry, finalized to care and research. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc.. This approach has been individuated in order to corroborate and integrate data from different resources and aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology.

Description:

The common way to collect patient information is frequently chaotic and inconvenient (sometimes even unsafe), particularly when dealing with rare diseases. The need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, suggested in 2013 to implement the Registry of Ollier Disease and Maffucci Syndrome (ROM). The ROM relies on an IT Platform named Genotype-phenotype Data Integration platform -GeDI.This solution, realized by a collaboration among Medical Genetic Department and a local software-house (NSI - Nier IT Solution), is a General Data Protection Regulation (GDPR)-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphanet code, ICD-10, Human Genome Variants Society, Findability Accessibility Interoperability Reusability Principles). GeDI is continuously implemented to improve management of persons with Ollier Disease and Maffucci Syndrome and to help researchers in analysing collected information. ROM is articulated in main sections: Personal data: it comprises general information, birth details and residence data Patient data: including the patients internal code, the hospital code and other details on patients Diagnosis: the diagnosis, the status (affected, suspect, etc.), age at diagnosis, comorbidities, allergies, etc. Genogram: a tool to design family transmission of the disease, flanked by info on diseases status of all included relatives Clinical events: records 23 signs and symptoms of Ollier Disease and Maffucci Syndrome and 12 additional items to describe the disease Genetic Analysis and Alteration: including technique, sample information, duration of analysis, etc. In addition, this section comprises detailed information on detected pathological variants (gene, international reference, DNA change, Protein change, genomic position, etc.) Visits: it includes the typology of the visit (genetic, orthopaedic, rehabilitation, paediatric, etc.), the date of the visit, treatment, prescription, imaging, etc. Surgeries: this section contains information on the surgeries type, the age of the patients, the site/localization of the procedures, etc. Documents: this repository is allowed to store all type of documents (radiological reports, imaging, consents, clinical reports, etc.) Consents: this section comprises a complete overview of all collected consents, including the date of collection. Samples: it comprises the type of samples (DNA, tissue, whole peripheral blood, etc.)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: January 2032
• Est. primary completion date: January 2032
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients affected by Ollier Disease and Maffucci Syndrome

Exclusion Criteria:

• Any condition unrelated to Ollier Disease and/or Maffucci Syndrome

Related Conditions & MeSH terms

• Maffucci Syndrome
• Ollier Disease
• Syndrome

Locations

Country	Name	City	State
Italy	Irccs Istituto Ortopedico Rizzoli	Bologna	Emilia Romagna

Sponsors (1)

Lead Sponsor	Collaborator
Luca Sangiorgi

Country where clinical trial is conducted

Italy, 

References & Publications (8)

Bertucci V, Krafchik BR. What syndrome is this? Ollier disease + vascular lesions: Maffucci syndrome. Pediatr Dermatol. 1995 Mar;12(1):55-8. doi: 10.1111/j.1525-1470.1995.tb00127.x. No abstract available. — View Citation

Herget GW, Strohm P, Rottenburger C, Kontny U, Krauss T, Bohm J, Sudkamp N, Uhl M. Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up. Neoplasma. 2014;61(4):365-78. doi: 10.4149/neo_2014_046. — View Citation

Pansuriya TC, Kroon HM, Bovee JV. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol. 2010 Jun 26;3(6):557-69. — View Citation

Pansuriya TC, Oosting J, Krenacs T, Taminiau AH, Verdegaal SH, Sangiorgi L, Sciot R, Hogendoorn PC, Szuhai K, Bovee JV. Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis. 2011 Jan 14;6:2. doi: 10.1186/1750-1172-6-2. — View Citation

Saiji E, Pause FG, Lascombes P, Cerato Biderbost C, Marq NL, Berczy M, Merlini L, Rougemont AL. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis. Virchows Arch. 2019 Nov;475(5):625-636. doi: 10.1007/s00428-019-02606-9. Epub 2019 Jun 25. — View Citation

Silve C, Juppner H. Ollier disease. Orphanet J Rare Dis. 2006 Sep 22;1:37. doi: 10.1186/1750-1172-1-37. — View Citation

Superti-Furga A, Spranger J, Nishimura G. Enchondromatosis revisited: new classification with molecular basis. Am J Med Genet C Semin Med Genet. 2012 Aug 15;160C(3):154-64. doi: 10.1002/ajmg.c.31331. Epub 2012 Jul 12. — View Citation

Tsao YP, Tsai CY, Chen WS. Maffucci Syndrome. J Rheumatol. 2015 Dec;42(12):2434-5. doi: 10.3899/jrheum.150216. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Longitudinal study of disease evolution (including prospective and retrospective data)	This outcome aims to investigate the evolution of Ollier Disease and Maffucci Syndrome during time.; Main clinical features evaluated: Height (cm) age-related (compared to growth chart); Number and localization of enchondromas; Number and localization of deformities; Number and localization of functional limitations; Site at malignant transformation (adult); Age at malignant transformation (adult); Number: count of enchondromas, deformities, etc. Localization: defined using bone affected, site (proximal, distal, etc.) and side (left, right, both); Those data will be collected both retrospectively and prospectively for all patients via physical examination, clinical reports and imaging.; An evaluation of these parameters will be performed at each visit to keep trace on the progression of the clinical manifestations. Data will be collected to define annualized rate of new clinical manifestations related to age, using analyses such as Kaplan-Meyer and surviving rate.	25 years
Primary	Natural History and Epidemiology in terms of clinical, genetic and functional evaluation	To maintain an established registry in order to assess epidemiology and natural history (such as incidence, prevalence, etc.).; Collection of: Physical examinations data: BMI (kg/m^2); Number and localization of sites affected by enchondromas; Presence/absence of angiomas; Localization and number of deformities; Localization and number of functional limitations; Surgical procedures disease-related: Type of surgeries; Number of surgeries; Site of surgeries; Age at surgeries; Genetics background: studies of somatic variants; Family history: anamnestic family information; Number: count of enchondromas, deformities, etc. Localization: defined using bone affected, site (proximal, distal, etc.) and side (left, right, both); Clinical, orthopaedic and functional features are updated at each follow up. Clinical reports, medical charts and imaging are the primary source of data.	25 years
Secondary	Genotype-Phenotype Correlation among clinical features and eventual molecular background	Despite the unclear genetic background of Ollier disease and Maffucci syndrome, the secondary outcome aims to correlate genotype and phenotype. This includes, but is not limited to clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations.	25 years